252 participants
Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants.
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-05-22
- Start Date:
- 2026-06-30
- Completion:
- 2027-12-30
Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions
- DRUG
- COMBINATION_PRODUCT
No Results Yet